• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch.基于 FibroTouch 分析非酒精性脂肪性肝病患者的临床特征及识别危险因素
Sci Rep. 2023 Sep 8;13(1):14812. doi: 10.1038/s41598-023-41596-2.
2
Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.超声衰减参数 FibroTouch 及肝脏硬度测量在评估非酒精性脂肪性肝病患者肝脂肪变及纤维化中的诊断性能。
Clin Transl Gastroenterol. 2021 Apr 13;12(4):e00323. doi: 10.14309/ctg.0000000000000323.
3
[Clinical study on FibroTouch and multi-parameter model for diagnosis of hepatic fibrosis in patients with chronic liver disease].[FibroTouch与多参数模型诊断慢性肝病患者肝纤维化的临床研究]
Zhonghua Gan Zang Bing Za Zhi. 2015 Apr;23(4):265-9. doi: 10.3760/cma.j.issn.1007-3418.2015.04.007.
4
FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.在伊朗班达尔阿巴斯,比较 FIB-4、APRI 和 AST/ALT 比值与 FibroScan 用于评估非酒精性脂肪性肝病患者的肝纤维化。
BMC Gastroenterol. 2021 Dec 3;21(1):453. doi: 10.1186/s12876-021-02038-3.
5
Gamma-Glutamyl Transpeptidase-to-Platelet ratio predicts liver fibrosis in patients with concomitant chronic hepatitis B and nonalcoholic fatty liver disease.γ-谷氨酰转肽酶/血小板比值预测合并慢性乙型肝炎和非酒精性脂肪性肝病患者的肝纤维化。
J Clin Lab Anal. 2022 Aug;36(8):e24596. doi: 10.1002/jcla.24596. Epub 2022 Jul 9.
6
Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.瞬时弹性成像用于评估 2 型糖尿病患者非酒精性脂肪性肝病的患病率:来自 CORDIAL 队列研究的证据。
Saudi J Gastroenterol. 2022 Nov-Dec;28(6):426-433. doi: 10.4103/sjg.sjg_73_22.
7
Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease.超声衰减参数评估肝脂肪变严重程度的最佳界值:来自经肝活检证实的脂肪性肝病患者队列的证据。
Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):430-435. doi: 10.1097/MEG.0000000000001746.
8
[Diagnostic value of liver stiffness measurement for the evaluation of liver fibrosis in nonalcoholic fatty liver].肝脏硬度测量对非酒精性脂肪性肝病肝纤维化评估的诊断价值
Zhonghua Gan Zang Bing Za Zhi. 2020 Jul 20;28(7):567-572. doi: 10.3760/cma.j.cn501113-20190302-00065.
9
Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.意大利和加拿大艾滋病毒感染高危非酒精性脂肪性肝病老年患者肝纤维化的诊断:两步法评估。
Lancet HIV. 2022 Mar;9 Suppl 1:S4. doi: 10.1016/S2352-3018(22)00069-8.
10
Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.多囊卵巢综合征女性的非酒精性脂肪性肝病:预测肝脂肪变性和纤维化的非侵入性指标评估
Hormones (Athens). 2014 Oct-Dec;13(4):519-31. doi: 10.14310/horm.2002.1493. Epub 2014 Nov 5.

引用本文的文献

1
Extracellular vesicles as biomarkers for metabolic dysfunction-associated steatotic liver disease staging using explainable artificial intelligence.使用可解释人工智能将细胞外囊泡作为代谢功能障碍相关脂肪性肝病分期的生物标志物
World J Gastroenterol. 2025 Jun 14;31(22):106937. doi: 10.3748/wjg.v31.i22.106937.
2
The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.肠道微生物群靶向治疗在非酒精性脂肪性肝病中的作用:一项系统评价和网状Meta分析
Front Nutr. 2025 Jan 6;11:1470185. doi: 10.3389/fnut.2024.1470185. eCollection 2024.
3
The Levels of Serum HBV Pre-Genomic RNA and Its Associated Factors Among HBV-Infected Patients: A Retrospective Cohort Study in Hangzhou, Zhejiang, China.乙肝病毒感染患者血清乙肝病毒前基因组RNA水平及其相关因素:中国浙江杭州的一项回顾性队列研究
Int J Gen Med. 2024 Oct 15;17:4669-4680. doi: 10.2147/IJGM.S480283. eCollection 2024.
4
Predictors of High Cardiovascular Risk Among Nonobese Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease in a Chinese Population [Letter].中国人群中非肥胖2型糖尿病合并非酒精性脂肪性肝病患者心血管高风险的预测因素[信函]
Diabetes Metab Syndr Obes. 2024 Mar 5;17:1115-1116. doi: 10.2147/DMSO.S464017. eCollection 2024.

本文引用的文献

1
Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.非酒精性脂肪性肝病患者的肝细胞癌:系统评价和荟萃分析:HCC 和脂肪变性或脂肪性肝炎。
Neoplasia. 2022 Aug;30:100809. doi: 10.1016/j.neo.2022.100809. Epub 2022 May 27.
2
Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review.解读非酒精性脂肪性肝病进展为非酒精性脂肪性肝炎的病理生理学:一项系统评价
Cureus. 2021 Sep 22;13(9):e18201. doi: 10.7759/cureus.18201. eCollection 2021 Sep.
3
Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.超声衰减参数 FibroTouch 及肝脏硬度测量在评估非酒精性脂肪性肝病患者肝脂肪变及纤维化中的诊断性能。
Clin Transl Gastroenterol. 2021 Apr 13;12(4):e00323. doi: 10.14309/ctg.0000000000000323.
4
Diagnostic Accuracy of FibroScan and Factors Affecting Measurements.FibroScan的诊断准确性及影响测量结果的因素
Diagnostics (Basel). 2020 Nov 12;10(11):940. doi: 10.3390/diagnostics10110940.
5
The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.胰岛素抵抗和糖尿病在非酒精性脂肪性肝病中的作用。
Int J Mol Sci. 2020 May 29;21(11):3863. doi: 10.3390/ijms21113863.
6
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.代谢相关脂肪性肝病新定义:国际专家共识声明。
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
7
Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease.用于非酒精性脂肪性肝病肝脂肪变性诊断和监测的定量超声方法
Theranostics. 2020 Mar 4;10(9):4277-4289. doi: 10.7150/thno.40249. eCollection 2020.
8
Application of transient elastography in nonalcoholic fatty liver disease.瞬时弹性成像在非酒精性脂肪性肝病中的应用。
Clin Mol Hepatol. 2020 Apr;26(2):128-141. doi: 10.3350/cmh.2019.0001n. Epub 2019 Nov 8.
9
Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: Single-center prospective study.FibroTouch 与 FibroScan 用于慢性肝病纤维化分期的比较:单中心前瞻性研究。
Dig Liver Dis. 2019 Sep;51(9):1323-1329. doi: 10.1016/j.dld.2019.02.009. Epub 2019 Feb 28.
10
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者肝脏疾病的无创评估。
Gastroenterology. 2019 Apr;156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18.

基于 FibroTouch 分析非酒精性脂肪性肝病患者的临床特征及识别危险因素

Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch.

机构信息

Department of Gastroenterology, Wuhan No.1 Hospital, Wuhan, China.

Department of Pancreatic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

出版信息

Sci Rep. 2023 Sep 8;13(1):14812. doi: 10.1038/s41598-023-41596-2.

DOI:10.1038/s41598-023-41596-2
PMID:37684380
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10491815/
Abstract

Our aim was to explore the correlation between ultrasound attenuation parameter (UAP) and liver stiffness measurement (LSM) based on FibroTouch (China) and clinical features in patients with non-alcoholic fatty liver disease (NAFLD), so as to provide a certain basis for the clinical application of FibroTouch in NAFLD. Hepatic steatosis and fibrosis in patients with NAFLD were graded according to FibroTouch, and the relationship between steatosis and fibrosis levels and clinical characteristics was retrospectively analyzed. Hepatic steatosis was positively related with weight, BMI, waist, hyperlipidemia, hyperuricemia, FBG, UA, TG, ALT, AST, GGT, LSM and hepatic fibrosis grading, and was negatively related with gender (male), age and AST/ALT ratio. Hepatic fibrosis was positively related with age, BMI, waist, hypertension, FBG, ALT, AST, GGT, NFS, APRI, FIB-4, UAP and hepatic steatosis grading, and was negatively related with blood platelet (PLT) counts. Moreover, BMI, waist, TG, ALT and LSM were independent risk factors of hepatic steatosis, while decreased PLT counts, AST and UAP were independent risk factors of hepatic fibrosis. Body mass parameters, metabolic risk factors and liver function indicators increase the risk of hepatic steatosis and fibrosis in patients with NAFLD, and UAP and LSM can interact with each other.

摘要

我们的目的是探讨基于 FibroTouch(中国)的超声衰减参数(UAP)与肝硬度测量(LSM)在非酒精性脂肪性肝病(NAFLD)患者中的相关性,并探讨其与临床特征的关系,为 FibroTouch 在 NAFLD 中的临床应用提供一定依据。根据 FibroTouch 对患者的肝脂肪变和肝纤维化程度进行分级,并对其与临床特征的关系进行回顾性分析。肝脂肪变与体重、BMI、腰围、高血脂、高尿酸血症、FBG、UA、TG、ALT、AST、GGT、LSM 和肝纤维化分级呈正相关,与性别(男)、年龄和 AST/ALT 比值呈负相关。肝纤维化与年龄、BMI、腰围、高血压、FBG、ALT、AST、GGT、NFS、APRI、FIB-4、UAP 和肝脂肪变分级呈正相关,与血小板(PLT)计数呈负相关。此外,BMI、腰围、TG、ALT 和 LSM 是肝脂肪变的独立危险因素,而 PLT 计数减少、AST 和 UAP 是肝纤维化的独立危险因素。体质量参数、代谢危险因素和肝功能指标增加了 NAFLD 患者肝脂肪变和纤维化的风险,且 UAP 和 LSM 可相互作用。